The company said that it is the exclusive distributor for FlexDex in the US, and is combining the Endoeye Flex 3D tech with FlexDex’s wristed needle-driver to improve minimal access surgery procedures. The device can be used during multiple procedure types including general and gynecological specialties.
“Olympus and FlexDex are redefining minimal access surgery in the OR. We expect this solution to offer surgeons the precision and control they desire without the burden of a complex and costly computer-aided robotic system. This will not only improve patient outcomes and satisfaction but also help healthcare institutions provide true value-based care,” Olympus prez Todd Usen said in a prepared statement.
Olympus said that 3D imaging tech, combined with FlexDex’s device, helps simplify suturing in difficult-to-reach areas by translating motions from the surgeon’s hand, wrist and arm into corresponding movements with the device.
“Through our Olympus partnership, FlexDex is going to disrupt the paradigm where surgeons and hospitals had to choose between high cost/high function and low cost/low function,” FlexDex CEO Dr. James Geiger said in a press release.
In June, Olympus said that it was partnering with accelerator MedTech Innovator.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.